erkel cell carcinoma (MCC) is a rare and very aggressive cutaneous neoplasm. 1 It arises from neuroendocrine cells within the basal layer of the epidermis and has a tendency to lymph node recurrence and distant metastases. [2] [3] It has higher mortality than melanoma with a high rate of 5-year-specific mortality (46%). 4 Surgery is a principle treatment modality at the local stage. However, most patients are treated with palliative radiochemotherapy because of metastatic disease. There is no standardized consensus in the treatment of the disease.
Contrast-enhanced computed tomography (ceCT) is generally used to evaluate the extent of disease. Nevertheless, it has some limitations such as lower detection rate for nodal disease, especially at the initial stage. Somatostatin receptor Widespread Metastatic Involvement in a Patient with Merkel Cell Carcinoma on 68 Ga-DOTATATE PET/CT: Case Report A AB BS ST TR RA AC CT T Merkel cell carcinoma (MCC) is an uncommon but very aggressive form of neuroendocrine tumor. It locates in the skin, in the basal layer of the epidermis, and it has higher mortality than melanoma with a high tendency to metastatic disease. Surgery is a principle treatment modality at the local stage. However, most patients are treated with palliative radiochemotherapy because of metastatic disease. There is no consensus in the treatment of the disease. In this case, we report the benefit of somatostatin receptor imaging with 68 Ga-labeled somatostatin analog in the evaluation of disease spread and its impact on therapy management. In (Indium-111)-labeled somatostatin analog in MCC. According to these reports, SR scintigraphy added no extra data to conventional imaging. 5 Positron-emission tomography (PET) with 68 Ga (Gallium-68)-labeled somatostatin analogs is more accurate than conventional SR imaging. 6 Nowadays,
68
Ga-labeled somatostatin analogs are preferred to SR scintigraphy. Molecular imaging with somatostatin analogs also has the advantage of being able to serve as a guide for peptide receptor radionuclide therapy (PRRT).
In this case, we report the benefit of SR-PET imaging in the evaluation of disease spread and its impact on therapy management.
CASE REPORT
A man aged 79 years presented with swelling and skin color change in the left leg. Excisional biopsy from the skin lesion resulted in MCC with extensive lymphovascular invasion and tumor-positive surgical margins. Metastatic disease was not detected by concurrent thoracoabdominal ceCT. At the end of the one-year follow-up period, enlargement in the left inguinal region was detected and fine needle aspiration biopsy revealed recurrence of MCC. Accordingly, the patient was referred to the Nuclear Medicine Department for restaging of disease using 68 Ga-DOTATATE PET/CT. Widespread intense uptake was shown in whole-body ( Figure 1a ) and lower-extremity (Figure 1b This case report has been prepared in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All subjects in the study gave written informed consent.
DISCUSSION
Merkel cell carcinoma is an aggressive neuroendocrine tumor of the skin. Sentinel lymph node biopsy (SLNB) is recommended for the initial evaluation of all patients with no evidence of lymph node metastasis. Gupta et al. reported that the recurrence rate was three times higher in patients who were SLNB positive compared with an SLNBnegative group. 7 Interestingly, a statistically significant association was found between SLNB status and recurrence and survival in the largest singlecenter study. 8 Fields et al. reported that the presence of lymphovascular invasion was a strong predictor of SLNB positivity. 8 In the present case, extensive lymphovascular invasion was seen histopathologically at the diagnosis. Unfortunately, SLNB was not performed at this stage. In-octreotide) added no extra data to conventional imaging. 6 Lu et al. also stated that 18 F-FDG PET/CT had better results than conventional SR scintigraphy for the detection of MCC. 9 In a recent meta-analysis, the sensitivity and specificity of 18 F-FDG PET/CT in the diagnostic performance with MCC was reported as 90% and 98%, respectively.
10 18 FDG-PET/CT has a role in the evaluation of the MCC because of the high incidence of regional and metastatic disease. Nowadays, SR imaging with 68 Ga-labeled somatostatin analogs are preferred to conventional SR scintigraphy owing to the high resolution of PET imaging. In the present case, we initially preferred SR imaging with 68 Ga DOTATATE instead of 18 F-FDG because of the patient's neuroendocrine history. Widespread intense uptake was shown by 68 Ga-DOTATATE PET/CT. Unfortunately, we did not have the chance to compare the results with 18 FDG PET imaging. Abgral et al. reported that FDG PET was more sensitive than the SR scintigraphy for staging of metastatic well-differentiated endocrine carcinoma with a high Ki-67 index. 5 In a small study, Belhocine et al. concluded that normal FDG PET findings could rule out MCCs with low Ki-67 indexes.
11 Again unfortunately, we did not have the Ki-67 index of the tumor so we could not evaluate the relationship between Ki-67 index and FDG uptake. However, 68 Ga-68 PET imaging has an advantage because it serve as guide for peptide receptor radionuclide therapy, although PRRT could not used in this case. We report an uncommon case of MCC with widespread somatostatin receptor expression detected in 68 Ga DOTATATE PET/CT. This case suggests a place for SR imaging in patients with neuroendocrine tumors to accurately stage and determine therapy management. 
